Primary sclerosing cholangitis: New approaches to diagnosis, surveillance and treatment

Digestive Diseases

Volumn 30, Issue SUPPL. 1, 2012, Pages 39-47

  Trauner, Michael ^a   Halilbasic, Emina ^a   Baghdasaryan, Anna ^a,b   Moustafa, Tarek ^c   Krones, Elisabeth ^b   Fickert, Peter ^b   Hofer, Harald ^a   Penner, Edward ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Bile acids; Cholangiocellular carcinoma; Cholestasis; Nuclear receptors

Indexed keywords

AZATHIOPRINE; CA 19-9 ANTIGEN; LITHOCHOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; URSODEOXYCHOLIC ACID;

ARTICLE; AUTOIMMUNE PANCREATITIS; BILE DUCT CARCINOMA; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER STAGING; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CHEMORADIOTHERAPY; CLINICAL PRACTICE; COLON CROHN DISEASE; COLONOSCOPY; COLORECTAL CANCER; DIAGNOSTIC ERROR; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SURVEILLANCE; DRUG MEGADOSE; END STAGE LIVER DISEASE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC THERAPY; ENTERITIS; EUROPE; FLUORESCENCE IN SITU HYBRIDIZATION; GALLBLADDER CANCER; GASTROINTESTINAL DYSPLASIA; HUMAN; LAPAROTOMY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; PANCREAS CANCER; PATIENT SELECTION; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROCTOCOLECTOMY; PROGNOSIS; ULCERATIVE COLITIS;

CHOLANGITIS, SCLEROSING; HUMANS; POPULATION SURVEILLANCE; URSODEOXYCHOLIC ACID;

EID: 84867713233     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000341123     Document Type: Article

References (55)

1. Weismüller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP: The challenges in primary sclerosing cholangitis -aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008; 48(suppl 1):S38-S57.
2. Cullen SN, Chapman RW: The medical management of primary sclerosing cholangitis. Semin Liver Dis 2006; 26: 52-61. (Pubitemid 43320727)
3. Krones E, Graziadei I, Trauner M, Fickert P: Evolving concepts in primary sclerosing cholangitis. Liver Int 2012; 32: 352-369.
4. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzén H, Almer S, Granath F, Broomé U: Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-327. (Pubitemid 34194790)
5. Boberg KM, Lind GE: Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol 2011; 25: 753-764.
6. Pollheimer MJ, Halilbasic E, Fickert P, Trauner M: Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2011; 25: 727-739.
7. Pollheimer MJ, Trauner M, Fickert P: Will we ever model PSC? -'it's hard to be a PSC model!'. Clin Res Hepatol Gastroenterol 2011; 35: 792-804.
8. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267.
9. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ, American Association for the Study of Liver Diseases: Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678.
10. Wiencke K, Boberg KM: Current consensus on the management of primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol 2011; 35: 786-791.
11. Björnsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, Boberg KM, Angulo P: The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008; 134: 975-980. (Pubitemid 351451987)
12. Halliday JS, Djordjevic J, Lust M, Culver EL, Braden B, Travis SP, Chapman RW: A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease. J Crohns Colitis 2012; 6: 174-181.
13. Charatcharoenwitthaya P, Angulo P, Enders FB, Lindor KD: Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology 2008; 47: 133-142. (Pubitemid 351171050)
14. Angulo P, Maor-Kendler Y, Lindor KD: Small-duct primary sclerosing cholangitis: A long-term follow-up study. Hepatology 2002; 35: 1494-1500. (Pubitemid 34966904)
15. Loftus EV Jr, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ: PSC-IBD: A unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-96. (Pubitemid 40007225)
16. Gossard AA, Angulo P, Lindor KD: Secondary sclerosing cholangitis: A comparison to primary sclerosing cholangitis. Am J Gastroenterol 2005; 100: 1330-1333. (Pubitemid 40904357)
17. Björnsson E, Chari ST, Smyrk TC, Lindor K: Immunoglobulin G4 associated cholangitis: Description of an emerging clinical entity based on review of the literature. Hepatology 2007; 45: 1547-1554. (Pubitemid 46918339)
18. Webster GJ, Pereira SP, Chapman RW: Autoimmune pancreatitis/IgG4- associated cholangitis and primary sclerosing cholangitis -overlapping or separate diseases? J Hepatol 2009; 51: 398-402.
19. Alswat K, Al-Harthy N, Mazrani W, Alshumrani G, Jhaveri K, Hirschfield GM: The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. Am J Gastroenterol 2012; 107: 56-63.
20. Oseini AM, Chaiteerakij R, Shire AM, Ghazale A, Kaiya J, Moser CD, Aderca I, Mettler TA, Therneau TM, Zhang L, Takahashi N, Chari ST, Roberts LR: Utility of serum immunoglobulin G4 distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology 2011; 54: 940-948.
21. Razumilava N, Gores GJ, Lindor KD: Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011; 54: 1842-1852.
22. Masuoka HC, Rosen CB: Transplantation for cholangiocarcinoma. Clin Liver Dis 2011; 15: 699-715.
23. Lankisch TO, Metzger J, Negm AA, Vosskuhl K, Schiffer E, Siwy J, Weismüller TJ, Schneider AS, Thedieck K, Baumeister R, Zürbig P, Weissinger EM, Manns MP, Mischak H, Wedemeyer J: Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 2011; 53: 875-884.
24. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F: High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814.
25. Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK: Meta-analysis: Ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 2011; 34: 901-910.
26. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M: Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002; 123: 1238-1251.
27. Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K: Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology 2010; 52: 197-203.
28. Imam MH, Sinakos E, Gossard AA, Kowdley KV, Luketic VA, Edwyn Harrison M, Mc-Cashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, DeCook AC, Enders F, Lindor KD: High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther 2011; 34: 1185-1192.
29. Gotthardt D, Stiehl A: Endoscopic retrograde cholangiopancreatography in diagnosis and treatment of primary sclerosing cholangitis. Clin Liver Dis 2010; 14: 349-358.
30. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M: 24-nor Ursodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130: 465-481. (Pubitemid 43202044)
31. Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, Vecchiotti S, Gonzalez FJ, Schoonjans K, Strazzabosco M, Fickert P, Trauner M: Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2 -/-(Abcb4 -/-) mouse cholangiopathy model by promoting biliary HCO3 -output. Hepatology 2011; 54: 1303-1312.
32. Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C, Fuchsbichler A, Gumhold J, Silbert D, Zatloukal K, Langner C, Maitra U, Denk H, Hofmann AF, Strazzabosco M, Trauner M: Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2 -/-mice. Hepatology 2009; 49: 1972-1981.
33. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, Harrison ME, Mc-Cashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Lindor KD: High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011; 106: 1638-1645.
34. Moustafa T, Fickert P, Magnes C, Guelly C, Thueringer A, Frank S, Kratky D, Sattler W, Reicher H, Sinner F, Gumhold J, Silbert D, Fauler G, Höfler G, Lass A, Zechner R, Trauner M: Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology 2012; 142: 140-151.e12.
35. Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüringer A, Leski K, Fickert P, Karpen SJ, Trauner M: Curcumin improves sclerosing cholangitis in Mdr2 -/-mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 2010; 59: 521-530.
36. Eksteen B, Miles A, Curbishley SM, Tselepis C, Grant AJ, Walker LS, Adams DH: Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10. K Immunol 2006; 177: 593-603. (Pubitemid 43939173)
37. Mizuno S, Hirano K, Tada M, Yamamoto K, Yashima Y, Yagioka H, Kawakubo K, Ito Y, Kogure H, Sasaki T, Arizumi T, Togawa O, Matsubara S, Nakai Y, Sasahira N, Tsujino T, Isayama H, Kawabe T, Omata M, Koike K. Bezafibrate for the treatment of primary sclerosing cholangitis. J Gastroenterol 2010; 45: 758-762.
38. Wagner M, Zollner G, Trauner M: Nuclear receptors in liver disease. Hepatology 2011; 53: 1023-1034.
39. Trauner M, Halilbasic E: Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011; 140: 1120-1125.e1-e12.
40. Hov JR, Keitel V, Schrumpf E, Häussinger D, Karlsen TH: TGR5 sequence variation in primary sclerosing cholangitis. Dig Dis 2011; 29: 78-84.
41. Torres J, de Chambrun GP, Itzkowitz S, Sachar DB, Colombel JF: Review article: Colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 497-508.
42. Hohenester S, Wenniger LM, Paulusma CC, van Vliet SJ, Jefferson DM, Elferink RP, Beuers U: A biliary HCO3 -umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 2012; 55: 173-183.
43. Gadaleta RM, Oldenburg B, Willemsen EC, Spit M, Murzilli S, Salvatore L, Klomp LW, Siersema PD, van Erpecum KJ, van Mil SW: Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-B signaling in the intestine. Biochim Biophys Acta 2011; 1812: 851-858.
44. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW: Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011; 60: 463-472.
45. Nijmeijer RM, Gadaleta RM, van Mil SW, van Bodegraven AA, Crusius JB, Dijkstra G, Hommes DW, de Jong DJ, Stokkers PC, Verspaget HW, Weersma RK, van der Woude CJ, Stapelbroek JM, Schipper ME, Wijmenga C, van Erpecum KJ, Oldenburg B, Dutch Initiative on Crohn, Colitis (ICC): Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. PLoS One 2011; 6:e23745.
46. Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, Di Tullio G, Palasciano G, Moustafa T, Halilbasic E, Trauner M, Moschetta A: Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2012; 142: 355-365.
47. Lindor KD: New treatment strategies for primary sclerosing cholangitis. Dig Dis 2011; 29: 113-116.
48. Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, Fava G, Francis H, Trozzi L, Benedetti A: Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut 2009; 58:990-997.
49. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauerbruch T, Paumgartner G: Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebo-controlled trial. Hepatology 1992;16:707-714.
50. Stiehl A: Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis. Scand J Gastroenterol Suppl 1994; 204:59-61. (Pubitemid 24302613)
51. Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336:691-695.
52. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-907. (Pubitemid 32959399)
53. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, Bell H, Gangsøy-Kristiansen M, Matre J, Rydning A, Wikman O, Danielsson A, Sandberg-Gertzén H, Ung KA, Eriksson A, Lööf L, Prytz H, Marschall HU, Broomé U: Highdose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-1472. (Pubitemid 41597389)
54. Pusl T, Beuers U: Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol 2006;12:3487-3495. (Pubitemid 43997026)
55. Rudolph G, Gotthardt DN, Kloeters-Plachky P, Kulaksiz H, Schirmacher P, Stiehl A: In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment. Dig Dis Sci 2011;56:3624-3630.